Enko Chem Reports Breakthrough Field Trial Success for Next-Generation Graminicide Portfolio
MYSTIC, Conn.--(BUSINESS WIRE)--Enko Chem, Inc., a leading AgTech company developing breakthrough, sustainable crop protection products, today announced results from its latest European field trials of product candidates from a novel graminicide portfolio developed to tackle the growing threat of herbicide-resistant weeds in cereal crops. These trials specifically revealed exceptional control of blackgrass in winter wheat paired with outstanding crop safety. Earlier trials in other regions of the world have already shown success against a range of other problematic grass weeds.
As stricter environmental and safety standards reduce the availability of conventional herbicides, growers face fewer options for managing persistent weeds that significantly reduce crop yields. Enko's next generation graminicides are safe and sustainable potential replacements for older products that address the evolving needs of both growers and regulators.
The European field trials were conducted across the United Kingdom and France, where herbicide-resistant blackgrass is known to cause crop yield losses of up to 70% in severe cases. Enko's innovative chemistry demonstrated superior performance compared to existing commercial standards.
Prior to Europe, Enko's North American spring trials demonstrated efficacy against other problematic warm-season grasses including crabgrass, giant foxtail, and goosegrass, while Australian tests addressed the growing threat of resistant annual ryegrass. The European results build upon this foundation of success across diverse geographies and weed species.
'Our product candidates integrate seamlessly into existing cereal crop systems and deliver industry-leading control of resistant grass species,' says Tony Klemm, CEO of Enko. 'Growers urgently need new, effective, and environmentally responsible chemistry. This graminicide portfolio is proof that a smarter discovery model delivers solutions – addressing key challenges like blackgrass resistance while advancing safe, sustainable agriculture.'
With development efforts reaching key benchmarks, Enko is actively collaborating with multiple industry partners to accelerate the global commercialization of its products.
For more information about Enko and its pipeline of crop protection solutions, visit www.enko.ag.
About Enko®
Enko (Enko Chem Inc.) designs safe and sustainable solutions to farmers' biggest crop threats today, from pest resistance to new diseases. By applying the latest drug discovery and development approaches from pharma to plants, Enko is bringing an innovation model to agriculture and meeting farmers' evolving needs. Founded in 2017, and led by a team of proven scientists, entrepreneurs, and agriculture industry veterans, Enko is backed by investors including the Gates Foundation, Anterra Capital, DYDK Capital, Nufarm, Novalis LifeSciences, Germin8 Ventures, TO Ventures Food, and Rabo Food & Agri Innovation Fund. Enko is headquartered in Mystic, Connecticut, USA. For more information, visit www.enko.ag.
Enko's Cautionary Statement Regarding Forward-Looking Statements
This press release contains forecasts, projections, goals, plans, and other forward-looking statements. Such forward-looking statements are based on Enko's assumptions, estimates, outlook, and other judgments made in light of information available at the time of preparation of such statements and involve both known and unknown risks and uncertainties. Accordingly, plans, goals, and other statements may not be realized as described, and actual financial results, success/failure or progress of development, and other projections may differ materially from those presented herein. The forward-looking statements are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Enko's control and that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. Enko does not intend to update any forward-looking statements appearing herein in the event of changing circumstances or otherwise, and such statements are current only as of the date they are made.
©Enko Chem, Inc., 62 Maritime Drive, Mystic, CT 06355 USA
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
an hour ago
- CNBC
Asian markets set to open higher as investors await Beijing-Washington trade meeting and China data
China Shenzhen Real444 | E+ | Getty Images Asian markets were set to climb Monday as investors awaited trade talks between the U.S. and China later in the day, following accusations between the two over breaching deal terms agreed in Geneva last month. Trade tensions are seemingly easing as China has reportedly granted temporary approvals for the export of rare earths, while jetliner Boeing Co has begun commercial jet deliveries to the Asian superpower. China is also slated to release a slew of data, including its consumer and wholesale inflation readings for May. Economists polled by Reuters expect consumer prices to have fallen by 0.2% year on year, while PPI is forecast to have declined by 3.2% from a year earlier.. Futures for Hong Kong's Hang Seng index stood at 23,801 pointing to a marginally higher open compared to the HSI's last close of 23,792.54. Japan's benchmark Nikkei 225 was set to open higher, with the futures contract in Chicago at 37,975 while its counterpart in Osaka last traded at 37,980, against the index's Friday close of 37,741.61. Australian markets are closed for a public holiday. U.S. equity futures were mostly flat in early Asian trade. All three key benchmarks on Wall Street jumped last Friday, after the non-farm payrolls data came in better-than-expected. U.S. payrolls climbed 139,000 in May, the Bureau of Labor Statistics reported Friday, above the Dow Jones forecast of 125,000 for the month but less than the downwardly revised 147,000 in April. The Dow Jones Industrial Average popped 443.13 points, or 1.05%, to close at 42,762.87. The blue-chip index was up more than 600 points at its highs of the session. Meanwhile, the the broad-based S&P 500 also gained 1.03% — surpassing the 6,000 level for the first time since late February — and settling at 6,000.36, while the Nasdaq Composite rallied 1.20%, to end at 19,529.95. — CNBC's Sean Conlon and Jesse Pound contributed to this report.
Business Wire
an hour ago
- Business Wire
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)-- SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; 'Modalis'), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM ® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM ® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. 'SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD,' stated Eva Chin, Executive Director of SOLVE FSHD. 'SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials.' 'We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103,' said Haru Morita, CEO of Modalis. 'This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM ® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM ® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD.' About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM ® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit
Yahoo
2 hours ago
- Yahoo
Insane amount Aussies could pay for coffee
Coffee may need to reach $12 a cup for Australia to compete with other countries for the sacred beans. Benchmark prices hit an all-time high in April, and industry insiders say Chinese demand for beans is squeezing prices in Australia. '(The) Chinese have very much converted from tea to coffee,' Essential Coffee chief executive Todd Hiscock told the ABC. 'They're buying up unprecedented levels of coffee supplies, often they're taking a whole Brazilian stock load in ways that's never been seen before.' Median prices per cup needed to increase to between $8 to $12, he said. 'We've got to come to the party and pay in a competitive global market,' Hiscock said. Brazil produces more than one-third of the world's coffee beans. The country battled through a drought in 2024 that was capped off with a cold snap. Combined, this slashed the overall harvests. As investors turn away from the volatile US, the Brazilian real has also climbed, disincentivising exports out of Brazil. Vietnam is the second-largest coffee producer. The El Nino weather pattern plunged Vietnam's coffee-growing regions into drought for the past two years, damaging the plants so badly that many will not fully recover for another two years. These international pressures, plus general inflation, are slicing margins at Australian cafes. A large player in the Australian coffee industry, Essential Coffee's wage bill has risen 9 per cent in two years, combined with a 29 per cent increase in rent and a 6 per cent rise in insurance. Mr Hiscock told the ABC the price of wholesale coffee had risen 119 per cent since November 2023. 'It's hard because people are very sensitive to their beloved coffee and when you move the price up, you find not just a lot of negative reaction, you find some very terse expletives,' he said.
